Hippocampal hypometabolism predicts cognitive decline from normal aging
This longitudinal study used FDG-PET imaging to predict and monitor cognitive decline from normal aging. Seventy-seven 50–80-year-old normal (NL) elderly received longitudinal clinical examinations over 6–14 years (561 person-years, mean per person 7.2 years). All subjects had a baseline FDG-PET sca...
Saved in:
Published in | Neurobiology of aging Vol. 29; no. 5; pp. 676 - 692 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.05.2008
|
Subjects | |
Online Access | Get full text |
ISSN | 0197-4580 1558-1497 1558-1497 |
DOI | 10.1016/j.neurobiolaging.2006.12.008 |
Cover
Summary: | This longitudinal study used FDG-PET imaging to predict and monitor cognitive decline from normal aging.
Seventy-seven 50–80-year-old normal (NL) elderly received longitudinal clinical examinations over 6–14 years (561 person-years, mean per person 7.2 years). All subjects had a baseline FDG-PET scan and 55 subjects received follow-up PET exams. Glucose metabolic rates (MRglc) in the hippocampus and cortical regions were examined as predictors and correlates of clinical decline.
Eleven NL subjects developed dementia, including six with Alzheimer's disease (AD), and 19 declined to mild cognitive impairment (MCI), on average 8 years after the baseline exam. The baseline hippocampal MRglc predicted decline from NL to AD (81% accuracy), including two post-mortem confirmed cases, from NL to other dementias (77% accuracy), and from NL to MCI (71% accuracy). Greater rates of hippocampal and cortical MRglc reductions were found in the declining as compared to the non-declining NL.
Hippocampal MRglc reductions using FDG-PET during normal aging predict cognitive decline years in advance of the clinical diagnosis. Future studies are needed to increase preclinical specificity in differentiating dementing disorders. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
ISSN: | 0197-4580 1558-1497 1558-1497 |
DOI: | 10.1016/j.neurobiolaging.2006.12.008 |